Oct. 29--Generic drug-maker Mylan Inc. sunk into the red in the third quarter after taking a charge to settle claims by the U.S. Justice Department that it inflated prices of drugs sold to Medicaid patients.

Cecil-based Mylan said this morning it lost $40 million, or 13 cents per share, for the three months ended Sept. 30. That compares with net income of $182.4 million, or 47 cents, in the year-ago period.

Excluding special items, Mylan said it earned 32 cents per share, beating analysts' consensus estimate of 27 cents.

Mylan CEO Robert Coury said that based on core results, the company was raising full-year earnings guidance to a range of $1.24 to $1.28 per share, excluding one-time items, up from $1.13 to $1.20.

In the most recent quarter, Mylan recorded an after-tax charge of $83 million to settle the dispute with the Justice Department. The settlement did not include an admission of wrongdoing. Mylan and other drug companies were accused of violating laws that require them to sell drugs to Medicaid at the lowest price they are sold to other customers.

Revenue for the third quarter was $1.26 billion, down from $1.66 billion. The year-earlier period included $455 million related to the company's sale of product rights to the blood pressure drug Bystolic.

Patricia Sabatini can be reached at psabatini@post-gazette.com or 412-263-3066.

Looking for more from the Post-Gazette? Join PG+, our members-only web site. You'll get exclusive sports content, opinion, financial information, discounts from retailers and restaurants, and more. Our introduction to PG+ gives you all the details.

-----

To see more of the Post-Gazette, or to subscribe to the newspaper, go to http://www.post-gazette.com.

Copyright (c) 2009, Pittsburgh Post-Gazette

Distributed by McClatchy-Tribune Information Services.

For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

NYSE:MYL,

A service of YellowBrix, Inc.